These data suggest that dual targeting of the YAP/TAZ and angiogenic pathways could be beneficial to limit primary tumor growth, as well as the intrinsic capacity to metastasize to the brain, though the influence of VM mediating the propensity of MBM at these early stages remain unknown. The gene discussed is YAP1; the disease is neoplasm.